Invention Grant
- Patent Title: Inhibitors of LTβR-NFκB signaling pathways for treating inflammation and cancer
-
Application No.: US16604674Application Date: 2018-04-11
-
Publication No.: US11590202B2Publication Date: 2023-02-28
- Inventor: Jonathan Bromberg , Wenji Piao , Yanbao Xiong
- Applicant: University of Maryland, Baltimore
- Applicant Address: US MD Baltimore
- Assignee: University of Maryland, Baltimore
- Current Assignee: University of Maryland, Baltimore
- Current Assignee Address: US MD Baltimore
- Agency: Riverside Law LLP
- International Application: PCT/US2018/027049 WO 20180411
- International Announcement: WO2018/191348 WO 20181018
- Main IPC: C07K14/715
- IPC: C07K14/715 ; C07K19/00 ; A61K38/17 ; C07K14/435 ; A61P29/00 ; A61P35/00
Abstract:
The present invention provides compositions and methods for selective inhibition of the classical or non-classical LTβR-NFκB signaling pathway. In some embodiments, the compositions and methods of the present invention are useful for treating or preventing tissue graft rejection, inflammation, contact hypersensitivity, and cancer by decreasing cell motility.
Public/Granted literature
- US20200085912A1 Compositions and Methods for Treating Inflammation and Cancer Public/Granted day:2020-03-19
Information query
